Biohaven (BHVN) Depreciation & Amortization (CF) (2021 - 2026)
Biohaven's (BHVN) quarterly Depreciation & Amortization (CF) came in at $2.4 million in Q1 2026, up 5.34% year-on-year from $2.2 million in Q1 2025, and down 8.05% quarter-over-quarter from $2.6 million in Q4 2025.
Biohaven (BHVN) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Biohaven has disclosed Depreciation & Amortization (CF) across 6 years of filings, most recently posting $2.4 million for Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $2.4 million, up 5.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.0 million (up 16.03% YoY), and the FY2025 annual result was $9.9 million, up 26.31% from the prior year.
- Depreciation & Amortization (CF) came in at $2.4 million for Q1 2026 at Biohaven, down from $2.6 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.1 million in Q3 2025 to a low of $250000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $1.9 million (2023), against an average of $1.7 million.
- Across the five-year window, Depreciation & Amortization (CF) slumped 49.78% in 2022 and jumped 559.6% in 2023, its largest moves.
- Biohaven's Depreciation & Amortization (CF) stood at $344000.0 in 2022, then surged by 450.58% to $1.9 million in 2023, then rose by 29.94% to $2.5 million in 2024, then gained by 4.55% to $2.6 million in 2025, then decreased by 8.05% to $2.4 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $2.4 million (Q1 2026), $2.6 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Biohaven | 1.62 Bn | 1.27 Bn | - | 2.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.37 Mn |
| Mar 31, 2026 | 2.37 Mn |
| Dec 31, 2025 | 2.57 Mn |
| Dec 31, 2025 | 2.57 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | 2.25 Mn |
| Mar 31, 2025 | 2.25 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Dec 31, 2023 | 1.89 Mn |